KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Finished Goods (2016 - 2018)

Historic Finished Goods for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Q4 2018 value amounting to $2.7 billion.

  • Teva Pharmaceutical Industries' Finished Goods fell 89.25% to $2.7 billion in Q4 2018 from the same period last year, while for Dec 2018 it was $2.7 billion, marking a year-over-year decrease of 89.25%. This contributed to the annual value of $2.7 billion for FY2018, which is 89.25% down from last year.
  • According to the latest figures from Q4 2018, Teva Pharmaceutical Industries' Finished Goods is $2.7 billion, which was down 89.25% from $2.7 billion recorded in Q3 2018.
  • Teva Pharmaceutical Industries' 5-year Finished Goods high stood at $2.8 billion for Q4 2016, and its period low was $2.1 billion during Q4 2015.
  • Moreover, its 5-year median value for Finished Goods was $2.7 billion (2017), whereas its average is $2.6 billion.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Finished Goods tumbled by 1164.78% in 2014, and later soared by 3814.63% in 2016.
  • Over the past 5 years, Teva Pharmaceutical Industries' Finished Goods (Quarter) stood at $2.3 billion in 2014, then dropped by 9.61% to $2.1 billion in 2015, then soared by 38.15% to $2.8 billion in 2016, then decreased by 5.05% to $2.7 billion in 2017, then decreased by 0.89% to $2.7 billion in 2018.
  • Its Finished Goods was $2.7 billion in Q4 2018, compared to $2.7 billion in Q3 2018 and $2.7 billion in Q2 2018.